A Randomized Parallel-group, Placebo-controlled, Double-blind, Eventdriven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511055-17-00

Acronym

MK-2060-007

Enrollment

Registered

2024-07-09

Start date

2021-11-25

Completion date

2025-02-11

Last updated

2024-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of arteriovenous graft thrombosis

Brief summary

Time to First AVG Thrombosis Event

Detailed description

Time to Each Arteriovenous Graft Thrombosis Event (First and Recurrent), Number of Participants who Experience One or More Adverse Events (AEs), Number of Major Bleeding Events or Clinically Relevant Non-Major Bleeding Events per International Society on Thrombosis (ISTH) Criteria, Number of Participants Who Discontinue Study Intervention Due to an AE

Interventions

DRUGMK-2060

DRUGPlacebo to MK-2060

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to First AVG Thrombosis Event	—

Secondary

Measure	Time frame
Time to Each Arteriovenous Graft Thrombosis Event (First and Recurrent), Number of Participants who Experience One or More Adverse Events (AEs), Number of Major Bleeding Events or Clinically Relevant Non-Major Bleeding Events per International Society on Thrombosis (ISTH) Criteria, Number of Participants Who Discontinue Study Intervention Due to an AE	—

Countries

Bulgaria, Czechia, Germany, Greece, Italy, Portugal, Romania, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026